Goldman Sachs reports 5.1% stake in THERAPEUTICS INC.

The Goldman Sachs Group, Inc. filed a Schedule 13G reporting shared voting and dispositive power over 991,363.52 shares of THERAPEUTICS INC.

Rhea-AI Filing Summary

The Goldman Sachs Group, Inc. filed a Schedule 13G reporting shared voting and dispositive power over 991,363.52 shares of THERAPEUTICS INC. (CUSIP 48576U205) representing 5.1% of the class as of 03/31/2026.

The filing is a joint disclosure with Goldman Sachs & Co. LLC and includes a Joint Filing Agreement plus exhibits describing the parent/subsidiary reporting structure and customary disclaimers about client accounts.

Insights

Institutional Ownership Specialist

Large broker-dealer reports a passive 5.1% stake in the issuer.

The disclosure lists shared voting and dispositive power over 991,363.52 shares as of 03/31/2026, filed on a Schedule 13G, which typically indicates passive or non-activist holdings under the filer’s chosen classification.

Exhibit language attributes ownership to a Goldman Sachs reporting unit and includes standard client-account disclaimers; cash-flow treatment is not stated in the excerpt and timing of any transactions is not disclosed in the provided excerpt.

Securities Compliance Analyst

Filing shows joint filing mechanics and parent/subsidiary attribution.

The submission contains a Joint Filing Agreement and an Exhibit describing that Goldman Sachs & Co. LLC is the operating subsidiary of GS Group holding the reported positions. The filing follows the Release rules for disaggregation and disclaimers.

Materiality is procedural: the filing documents ownership levels and reporting relationships; subsequent filings would disclose any change in voting or disposition if and when they occur.

Key Figures

Filing type: Schedule 13G Shares reported: 991,363.52 shares Percent of class: 5.1% +2 more

5 metrics

Filing type Schedule 13G Disclosure of beneficial ownership

Shares reported 991,363.52 shares shared voting and dispositive power

Percent of class 5.1% as of 03/31/2026

CUSIP 48576U205 THERAPEUTICS INC. common stock

Filing date / signature date 04/03/2026 Exhibit signatures dated

Key Terms

Schedule 13G, shared dispositive power, Joint Filing Agreement, disaggregated ownership

4 terms

Schedule 13G regulatory

"filed a Schedule 13G reporting shared voting and dispositive power"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

shared dispositive power financial

"Shared Dispositive Power 991,363.52 reported on the cover page"

Joint Filing Agreement regulatory

"EXHIBIT (99.1) JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)"

disaggregated ownership regulatory

"does not reflect securities beneficially owned by operating units disaggregated from the Reporting Units"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake in THERAPEUTICS INC. (KPTI) does Goldman Sachs report?

Goldman Sachs reports shared voting and dispositive power over 991,363.52 shares, representing 5.1% of the class as of 03/31/2026. The position is disclosed on a joint Schedule 13G filing with related exhibits.

Does the Schedule 13G filing indicate active control by Goldman Sachs?

No. The filing is a Schedule 13G, which is commonly used for passive or non‑activist holdings. The exhibits describe reporting units and include standard disclaimers about client accounts and disaggregated ownership.

Which entities filed the ownership disclosure for KPTI?

The filing was made jointly by The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC. A Joint Filing Agreement and exhibits explain the parent/subsidiary reporting arrangement and authority to amend the statement.

What does the filing say about client accounts and beneficial ownership?

The exhibit disclaims beneficial ownership of securities held in client accounts or certain investment entities where ownership is disaggregated, per the referenced Release No. 34-39538, aligning with customary broker/dealer disclosures.

What identifier and date are associated with this Schedule 13G for KPTI?

The filing references CUSIP 48576U205 for THERAPEUTICS INC. and reports the position as of 03/31/2026, with signatures dated 04/03/2026 on the joint filing exhibits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/12/2026 - 03:57 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

KARYOPHARM THERAPEUTICS INC.

(Name of Issuer)

Common Stock, $0.0001 per value

(Title of Class of Securities)

48576U205

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 48576U205

1

Names of Reporting Persons

THE GOLDMAN SACHS GROUP, INC.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 991,363.52
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 991,363.52

9

Aggregate Amount Beneficially Owned by Each Reporting Person

991,363.52

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

HC, CO

SCHEDULE 13G

CUSIP Number(s): 48576U205

1

Names of Reporting Persons

GOLDMAN SACHS & CO. LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NEW YORK

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 991,363.52
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 991,363.52

9

Aggregate Amount Beneficially Owned by Each Reporting Person

991,363.52

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

BD, OO, IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: KARYOPHARM THERAPEUTICS INC.
(b)	Address of issuer's principal executive offices: 85 WELLS AVENUE, SECOND FLOOR, NEWTON, X1, 02459
Item 2.
(a)	Name of person filing: THE GOLDMAN SACHS GROUP, INC.| GOLDMAN SACHS & CO. LLC
(b)	Address or principal business office or, if none, residence: The Goldman Sachs Group, Inc. 200 West Street New York, NY 10282| Goldman Sachs & Co. LLC 200 West Street New York, NY 10282
(c)	Citizenship: THE GOLDMAN SACHS GROUP, INC. - Delaware| GOLDMAN SACHS & CO. LLC - New York
(d)	Title of class of securities: Common Stock, $0.0001 per value
(e)	CUSIP Number(s): 48576U205
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s).
(b)	Percent of class: See the response(s)to Item 11 on the attached cover page(s).
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s).
	(ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s).
	(iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s).
	(iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s).
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit (99.2)
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

THE GOLDMAN SACHS GROUP, INC.

Signature:	Name: Abhilasha Bareja
Name/Title:	Attorney-in-fact
Date:	04/03/2026

GOLDMAN SACHS & CO. LLC

Signature:	Name: Abhilasha Bareja
Name/Title:	Attorney-in-fact
Date:	04/03/2026

Exhibit Information

EXHIBIT (99.1) JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.0001 per value, of KARYOPHARM THERAPEUTICS INC. and further agree to the filing of this agreement as an Exhibit thereto. In addition, each party to this Agreement expressly authorizes each other party to this Agreement to file on its behalf any and all amendments to such Statement on Schedule 13G. Date: 04/03/2026 THE GOLDMAN SACHS GROUP, INC. By:/s/ Abhilasha Bareja ---------------------------------------- Name: Abhilasha Bareja Title: Attorney-in-fact GOLDMAN SACHS & CO. LLC By:/s/ Abhilasha Bareja ---------------------------------------- Name: Abhilasha Bareja Title: Attorney-in-fact EXHIBIT (99.2) ITEM 7 INFORMATION The securities being reported on by The Goldman Sachs Group, Inc. ("GS Group"), as a parent holding company, are owned, or may be deemed to be beneficially owned, by Goldman Sachs & Co. LLC ("Goldman Sachs"), a broker or dealer registered under Section 15 of the Act and an investment adviser registered under Section 203 of the Investment Advisers Act of 1940. Goldman Sachs is a subsidiary of GS Group. EXHIBIT (99.3) ITEM 4 INFORMATION *In accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned by certain operating units (collectively, the "Goldman Sachs Reporting Units") of The Goldman Sachs Group, Inc. and its subsidiaries and affiliates (collectively, "GSG"). This filing does not reflect securities, if any, beneficially owned by any operating units of GSG whose ownership of securities is disaggregated from that of the Goldman Sachs Reporting Units in accordance with the Release. The Goldman Sachs Reporting Units disclaim beneficial ownership of the securities beneficially owned by (i) any client accounts with respect to which the Goldman Sachs Reporting Units or their employees have voting or investment discretion or both, or with respect to which there are limits on their voting or investment authority or both and (ii) certain investment entities of which the Goldman Sachs Reporting Units act as the general partner, managing general partner or other manager, to the extent interests in such entities are held by persons other than the Goldman Sachs Reporting Units.